Jeffrey W. Sherman - 27 Nov 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
27 Nov 2023
Net transactions value
+$10,098
Form type
4
Filing time
29 Nov 2023, 16:09:05 UTC
Previous filing
06 Oct 2023
Next filing
11 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $10,098 +5,400 $1.87 5,400 27 Nov 2023 By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001 F1
holding XERS Common Stock 107,878 27 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.